FDA Pushes Back Orforglipron Decision to April as National Priority Voucher Program Hits Early Turbulence
The FDA has delayed its decision on Eli Lilly's oral obesity pill orforglipron from March 28 to April 10, alongside delays for three other drugs in the new expedited review program.
Overview
The U.S. Food and Drug Administration has pushed back its target decision date for Eli Lilly’s oral obesity drug orforglipron from March 28 to April 10, 2026, marking an early setback for the agency’s Commissioner’s National Priority Voucher (CNPV) program. The delay affects not only orforglipron but also three other drugs that received expedited review vouchers, raising questions about whether the program can deliver on its promise to compress FDA review timelines from the standard 10 to 12 months down to one or two months.
Orforglipron would be the first oral small-molecule GLP-1 receptor agonist approved for obesity treatment without dietary restrictions, potentially transforming a market currently dominated by injectable therapies.
What We Know
The Drug and Its Clinical Profile
Orforglipron is a once-daily oral pill that activates the GLP-1 receptor, the same biological target used by injectable blockbusters like Wegovy and Zepbound. Unlike Novo Nordisk’s recently approved oral semaglutide (Wegovy pill), which requires patients to wait 30 minutes before eating, orforglipron can be taken without food or water restrictions.
In the Phase 3 ATTAIN-1 trial published in The New England Journal of Medicine, participants without diabetes who took the highest dose of orforglipron (36 mg) lost a mean of 11.2 percent of their body weight over 72 weeks, compared with 2.1 percent for placebo. Nearly 60 percent of participants on the highest dose achieved at least 10 percent weight loss, and about 40 percent lost 15 percent or more.
A separate maintenance trial, ATTAIN-MAINTAIN, demonstrated that patients who switched from injectable semaglutide or tirzepatide to oral orforglipron maintained nearly all of their prior weight loss, a key finding for patients seeking to move away from injections.
The National Priority Voucher Program
The CNPV program launched in June 2025 with the goal of accelerating FDA reviews for drugs that advance national priorities such as addressing unmet medical needs, boosting domestic manufacturing, and reducing drug prices. Orforglipron was among 15 drugs selected in the program’s first two rounds.
Reuters had reported that agency leaders initially aimed for a March 28 decision, hoping to beat the original May 20 PDUFA deadline by nearly two months. The revised April 10 date still represents a faster-than-normal review, but falls short of the one-to-two-month turnaround the program initially advertised.
Other Drugs Affected
The delay extends beyond orforglipron. Three other CNPV recipients also saw their timelines pushed back:
- Sanofi’s teplizumab (Tzield), for type 1 diabetes prevention, was delayed by over a month following safety signals that included two seizures, one blood clotting episode, and one patient death.
- Disc Medicine’s bitopertin, for erythropoietic protoporphyria, was pushed back two weeks amid questions about efficacy and potential abuse risk.
- Boehringer Ingelheim’s zongertinib, for HER2-mutated non-small cell lung cancer, had its timeline adjusted as well.
What We Don’t Know
The FDA has not disclosed the specific reasons for extending orforglipron’s review, and it remains unclear whether the delay stems from safety questions, manufacturing documentation, or simply the logistical reality of reviewing a complex new drug application faster than any previous obesity treatment.
It is also uncertain whether the CNPV program’s compressed timelines are sustainable at scale. The program selected 15 drugs in its first wave alone, and regulatory staff must balance thoroughness with speed. Whether the April 10 date holds firm or slips further remains to be seen.
Analysis
The delay is modest in absolute terms — roughly two weeks — but it carries symbolic weight. The CNPV program was designed to demonstrate that the FDA could move as fast as industry and patients demanded, provided companies met commitments on pricing and domestic manufacturing. Four delays out of the first cohort suggests the program is encountering the same tensions between speed and rigor that have defined drug regulation for decades.
For the obesity drug market specifically, the timing matters. Novo Nordisk’s oral Wegovy pill reached U.S. pharmacies in early January 2026 at roughly $149 per month without insurance, giving it a head start in the oral GLP-1 category. Every week of delay for orforglipron is a week of uncontested market access for its rival. If approved, orforglipron’s lack of dietary restrictions could prove to be a meaningful differentiator in patient adherence, but only once it reaches the market.